Answers are grounded in this paper and cite their sources.
In recent times, bitter melon extract (BME) has gained significant attention for its anticancer efficacy against various malignancies. In this issue, Sur and colleagues show that BME prevents the development of 4-nitronitroquinoline 1-oxide–induced oral dysplasia and squamous cell carcinoma (SCC) in an immunocompetent mouse model. Importantly, gene ontology and pathway analyses revealed an elevated expression of s100a9, IL23a, IL1β, and PDCD1/PD1 of immune system during oral cancer development, which was significantly suppressed by BME. Overall, this study demonstrates the potential clinical benefits of BME in preventing and delaying the progression of oral dysplasia to SCC. Cancer Prev Res; 11(4); 185–6.
No takes yet. Share an insight, caveat, or question.
Chinthalapally V. Rao (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: